Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, Matthew Weinstock et al.|The Lancet Oncology|2021Cited by 102
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)Benjamin L. Lampson, Matthew S. Davids, Svitlana Tyekucheva et al.|Blood|2019Cited by 31
Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)Matthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|Blood|2020Cited by 19
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's SyndromeJennifer L. Crombie, Matthew S. Davids, Svitlana Tyekucheva et al.|Blood|2020Cited by 14